ResMed (RMD) CFO discloses 1,000-share planned stock sale in Form 4

Rhea-AI Filing Summary

ResMed Inc.'s Chief Financial Officer reported a small planned share sale. On 01/02/2026, the CFO sold 1,000 shares of ResMed common stock at a price of $241.75 per share in an open market transaction coded as a sale. The filing shows that after this transaction, the officer directly beneficially owns 86,495 shares of ResMed common stock.

The transaction was made under a Rule 10b5-1 trading plan that was adopted on February 19, 2025, indicating it was pre-arranged under SEC rules rather than a discretionary trade at the time of sale.

Insider Trade Summary

Net Seller: 1,000 shares ($241,750)

Net Sell 1 txn

Insider Sandercock Brett

Role Chief Financial Officer

Sold 1,000 shs ($242K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	1,000	$241.75	$242K

Holdings After Transaction: ResMed Common Stock — 86,495 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	01/02/2026		S(1)		1,000	D	$241.75	86,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

	/s/ Brett Sandercock, Chief Financial Officer	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed Inc (RMD) report in this Form 4?

ResMed Inc reported that its Chief Financial Officer sold 1,000 shares of ResMed common stock on 01/02/2026 at a price of $241.75 per share.

Who is the insider involved in the latest ResMed Inc (RMD) Form 4 filing?

The insider is ResMed Inc's Chief Financial Officer, who is an officer of the company and filed the Form 4 as a single reporting person.

How many ResMed Inc (RMD) shares does the CFO own after the reported sale?

Following the reported transaction, the Chief Financial Officer beneficially owns 86,495 shares of ResMed common stock in direct ownership.

Was the ResMed Inc (RMD) CFO trade made under a Rule 10b5-1 plan?

Yes. The filing explains that the sale was conducted under a Rule 10b5-1 trading plan that was adopted on February 19, 2025.

What type of security was involved in the ResMed Inc (RMD) insider transaction?

The transaction involved ResMed common stock, reported in Table I for non-derivative securities, with no derivative securities reported in Table II.

How is the transaction coded in the ResMed Inc (RMD) Form 4?

The transaction is reported with code S in Table I, indicating a sale of common stock by the insider.